Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03621982
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:26.726574+00:00
Published At
2024-06-13T00:00:00+00:00
Record Updated At
2024-06-13
Results Posted At
2024-06-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Head and Neck Cancer Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Gastric Cancer", "Esophageal Cancer", "Pancreas Cancer", "Bladder Cancer", "Renal Cell Carcinoma", "Melanoma", "Triple-negative Breast Cancer", "Ovarian Cancer", "Colo-rectal Cancer", "Fallopian Tube Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-06-13"
protocolSection.identificationModule.nctId
"NCT03621982"
protocolSection.identificationModule.officialTitle
"A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2024-06-13"

Study condition terms

  • Head and Neck Cancer Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Pancreas Cancer (protocolSection.conditionsModule.conditions)
  • Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Triple-negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Colo-rectal Cancer (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.